$PRVA

Morris Matthew Shawn sold $3.6M of PRVA

Morris Matthew Shawn sold 135,498 shares of Privia Health Group, Inc. (PRVA) at an average of $26.32 ($25.72–$26.93, $3.57M total) across 3 trades over 2026-06-30 to 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Morris Matthew Shawn
Published Jul 2, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 7:39 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRVA
Neutral
medium confidence
Mentioned
$PRVA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRVANeutralLow
01

Why it matters

The disclosure updates the record of insider activity and may influence short-term sentiment, but it does not introduce new company-specific operating or financial information.

02

Market read

Traders may note the insider sale size ($3.57M) and 10b5-1 context, but there is no fundamental catalyst in the text.

03

What to watch

The filing does not state motivations, and the sales were spread across three trades with a stated weighted average price, limiting inference about timing or new information.

Relevance 5/10Novelty 3/10Timing: filed 2026-07-02 for sales executed 2026-06-30 to 2026-07-01

Background

This is an SEC Form 4 insider transaction for Privia Health Group, Inc. (PRVA), reported by a director.

Company-level read

Ticker impact

$PRVANeutralMedium confidence
Context

Privia Health Group director Morris Matthew Shawn sold $3.57M of PRVA shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

Form 4 shows a director’s planned open-market sale with a 10b5-1 plan, which typically reduces signaling value versus discretionary selling. The article provides no accompanying company news (earnings, guidance, deals, or regulatory actions).

Market effects

Minimal; insider sale in a single healthcare services name does not materially change sector fundamentals.

None indicated.

None indicated.

Counterpoint

A large director sale can still be interpreted as risk management or diversification, but it is often not bearish when executed under a 10b5-1 plan.

Key entities

  • Privia Health Group, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Morris Matthew Shawn

    Director who sold 135,498 PRVA shares under a pre-arranged 10b5-1 plan.

Related articles

$PRVAHighAI 9/10

Privia Health Group, Inc. (PRVA): Results of Operations and Financial Condition

Privia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q26earningrelease.htm EX-99.1 Document Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for